Patents by Inventor Brian Dymock
Brian Dymock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9624242Abstract: The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use of the citrate salt in the treatment of certain medical conditions.Type: GrantFiled: February 13, 2015Date of Patent: April 18, 2017Assignee: CTI BIOPHARMA CORP.Inventors: Brian Dymock, Cheng Hsia Angeline Lee, Anthony Deodaunia William
-
Publication number: 20150322084Abstract: The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use of the citrate salt in the treatment of certain medical conditions.Type: ApplicationFiled: February 13, 2015Publication date: November 12, 2015Inventors: Brian Dymock, Cheng Hsia Angeline Lee, Anthony Deodaunia William
-
Patent number: 9120815Abstract: Provided herein are salt forms of macrocyclic protein kinase inhibitors, pharmaceutical compositions containing the same, methods of making and using these compounds and compositions to treat proliferative disease mediated by kinase activity.Type: GrantFiled: February 4, 2011Date of Patent: September 1, 2015Assignee: Tragara Pharmaceuticals, Inc.Inventors: Robert K. Mansfield, Tracy Lawhon, Brian Dymock
-
Patent number: 9062074Abstract: The present invention relates to certain salts of a 9E-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use of the citrate salt in the treatment of certain medical conditions.Type: GrantFiled: July 14, 2010Date of Patent: June 23, 2015Assignee: CTI BioPharma Corp.Inventors: Brian Dymock, Cheng H. Lee, Anthony D. William
-
Patent number: 8987243Abstract: The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26triaza-tetra-cyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the maleate salt of this compound. The invention also relates to pharmaceutical compositions containing this salt and methods of use of the salt in the treatment of certain medical conditions.Type: GrantFiled: December 9, 2009Date of Patent: March 24, 2015Assignee: CTI Biopharma Corp.Inventors: Brian Dymock, Cheng H. Lee, Anthony D. William
-
Patent number: 8980873Abstract: The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use of the citrate salt in the treatment of certain medical conditions.Type: GrantFiled: December 9, 2009Date of Patent: March 17, 2015Assignee: CTI Biopharma Corp.Inventors: Brian Dymock, Cheng H. Lee, Anthony D. William
-
Publication number: 20130150378Abstract: Provided herein are salt forms of macrocyclic protein kinase inhibitors, pharmaceutical compositions containing the same, methods of making and using these compounds and compositions to treat proliferative disease mediated by kinase activity.Type: ApplicationFiled: February 4, 2011Publication date: June 13, 2013Inventors: Robert K. Mansfield, Tracy Lawhon, Brian Dymock
-
Publication number: 20120196876Abstract: The present invention relates to certain salts of a 9E-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5). 1(14,18)]hexacosa-1(24),2,4,9, 14,16,18(26),20,22-nonaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use of the citrate salt in the treatment of certain medical conditions.Type: ApplicationFiled: July 14, 2010Publication date: August 2, 2012Applicant: S*Bio Pte Ltd.Inventors: Brian Dymock, Cheng Hsia Angeline Lee, Anthony Deodaunia William
-
Publication number: 20110294831Abstract: The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use of the citrate salt in the treatment of certain medical conditions.Type: ApplicationFiled: December 9, 2009Publication date: December 1, 2011Applicant: S*BIO Pte Ltd.Inventors: Brian Dymock, Cheng H. Lee, Anthony D. William
-
Publication number: 20110263616Abstract: The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26triaza-tetra-cyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the maleate salt of this compound. The invention also relates to pharmaceutical compositions containing this salt and methods of use of the salt in the treatment of certain medical conditions.Type: ApplicationFiled: December 9, 2009Publication date: October 27, 2011Applicant: S*BIO Pte Ltd.Inventors: Brian Dymock, Cheng H. Lee, Anthony D. William
-
Publication number: 20070213328Abstract: The use of compounds of formula (I) in therapy, particularly for the treatment of a disorder mediated by excessive or inappropriate HSP90 activity formula (I), wherein R2 is a group of formula (IA): -(Ar1)m-(Alk1)p-(Z)r-(Alk2)s-Q (IA) Ar1, Alk1, Z, Alk2 and Q being as defined in the specification; m, p, r and s are independently 0 or 1; R3 is hydrogen, an optional substituent, or an optionally substituted (C1-C6)alkyl, aryl or heteroaryl radical; and R4 is a carboxylic ester, carboxamide or sulfonamide group; or a salt, N-oxide, hydrate, or solvate thereof.Type: ApplicationFiled: October 5, 2004Publication date: September 13, 2007Applicant: Vernalis (Cambridge) LimitedInventors: Martin Drysdale, Brian Dymock, Xavier Barril-Alonso
-
Publication number: 20070112192Abstract: Compounds of formula (IA) or (IB) or salts, N-oxides. hydrates or solvates thereof are Inhibitors of HSP90, and useful in the treatment of, for example, cancer: formula (IA), formula (IB) wherein Ar is an aryl or heteroaryl radical which is linked via a ring carbon, and which is substituted by a hydroxy group on a carbon in the 2-position, and which is otherwise either unsubstituted or optionally substituted; R1 is hydrogen or optionally substituted C1-C6 alkyl; R2 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C1-C6 alkyl, C1-C6alkenyl, or C1-C6 alkynyl; or a carboxyl, carboxamide or carboxyl ester group; and R3 is a carboxamide group.Type: ApplicationFiled: December 4, 2003Publication date: May 17, 2007Applicants: VERNALIS (CAMBRIDGE) LIMITED, CANCER RESEARCH TECHNOLOGY LTD., THE INSTITUTE OF CANCER RESEARCHInventors: Mandy Beswick, Paul Brough, Martin Drysdale, Brian Dymock
-
Publication number: 20070072855Abstract: Compounds of formula (I) are inhibitors of HSP90 activity, and useful in the treatment of proliferative disease such as cancers: wherein R1, R2 and R3 are as defined in the specification, and X is —OR4 or —NR4R5 wherein R4 and R5 independently represent hydrogen or optionally substituted C1-C6 alkyl, or R4 and R5 taken together with the nitrogen to which they are attached form an optionally substituted nitrogen-containing ring having 5-8 ring atoms.Type: ApplicationFiled: April 23, 2004Publication date: March 29, 2007Applicants: Vernalis (cambridge) Limited, Cancer Research Technology Ltd, The Institute of Cancer ResearchInventors: Xavier Barrilalonso, Brian Dymock, Martin Drysdale
-
Publication number: 20070043044Abstract: Compounds of formula (1) are inhibitors of HSP90 activity in vitro or in vivo, and of use in the treatment of inter alia, cancer wherein R2 is a group of formula —(Ar1)m-(Alk1)P-(Z)r-(Alk2)S-Q wherein Ar1 is an optionally substituted aryl or heteroaryl radical, Alk? and Alk 2 are optionally substituted divalent C1-C3 alkylene or C2-C3 alkenylene radicals, m, p, r and s are independently 0 or 1, Z is —0—, —S—, —(C?O)—, —(C?S)—, —S02-, —C(?O)O—, —C(?O)NRA—, —C(?S)NRA—, —S02NRA—, —NRAC(?O)_, —NRAS02- or —NRA—wherein RA is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R3 is hydrogen, an optional substituent, or an optionally substituted (C1-C6)alkyl, aryl or heteroaryl radical; and R4 is a carboxylic ester, carboxamide or sulfonamide group.Type: ApplicationFiled: August 26, 2004Publication date: February 22, 2007Applicants: VERNALIS (CAMBRIDGE) LIMITED, CANCER RESEARCH TECHNOLOGY LTD., THE INSTITUTE OF CANCER RESEARCH, BARRIL-ALONSO, Xavier (ES)Inventors: Brian Dymock, Martin Drysdale, Christofe Fromont, Allan Jordan, Xavier Barril-Alonso
-
Publication number: 20060241106Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: (A), (B) wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO2—, —C(?O)O—, —C(?O)NRA—, —C(?S)NRA—, —SO2NRA—, —NRAC(?O)—, —NRASO2— or —NRA— wherein RA is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is (i) a group of formula (IA) above or (ii) a carboxamide radical; or (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk1)p-(Z)r-(Alk2)s-Q wherein Q, Alk1, Alk2, Z, p, r and s are as defined above in relation to group (IA); andType: ApplicationFiled: February 9, 2004Publication date: October 26, 2006Inventors: Martin Drysdale, Brian Dymock, Harry Finch, Paul Webb, Edward McDonald, Karen James, Kwai Cheung, Thomas Matthews
-
Publication number: 20060235058Abstract: Compound of a compound of formula (1) or a salt, N-oxide, hydrate or solvate thereof, in the preparation of a composition for inhibition of HSP90 activity: wherein ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms, for example 1,2,3-triazolyl or a 1,2,4-triazolyl or a tetrazolyl ring; and R1 R2 R3 are as defined in the specification are inhibitors of HSP90 and therefore of use in the treatment of, for example, cancers, viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor, or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie /CJD, Huntingdon's and Alzheimer's disease.Type: ApplicationFiled: June 24, 2004Publication date: October 19, 2006Applicants: Vernalis (Cambridge) Limited, Cancer Research Technology Ltd., The Institute of Cancer ResearchInventors: Kwai Cheung, Brian Dymock, Edward McDonald, Martin Drysdale
-
Publication number: 20060148817Abstract: Compounds of formula (IA) or (IB) or a salt, N-oxide, hydrate or solvate thereof are inhibitors of HSP90, and are of value in the treatment of diseases responsive to HSP90 inhibition such as cancers.Type: ApplicationFiled: December 18, 2003Publication date: July 6, 2006Applicants: Vernalis (Cambridge) Limited, Cancer Research Technolgy Technology Ltd., The Institute of Cancer ResearchInventors: Christine Beswick, Martin Drysdale, Brian Dymock, Edward McDonald
-
Publication number: 20050222230Abstract: The present invention pertains to the use of certain 3,4-diarylpyrazoles of formula (I), both in vitro and in vivo, to inhibit heat shock protein 90 (HSP90), and in the treatment of conditions mediated by HSP90, including, for example, cancer; wherein: Ar3 is independently: a C5-20aryl group, and is optionally substituted; Ar4 is independently: a C5-20aryl group, and is optionally substituted; R5 is independently: hydrogen; halo; hydroxy; ether; formyl; acyl; carboxy; ester, acyloxy; oxycarbonyloxy; amido; acylamido; aminocarbonyloxy; tetrazolyl; amino; nitro; cyano; azido; sulfhydryl; thioether; sulfonamido; C1-7alkyl; C3-20heterocycyl; or C5-20aryl; R<SP>N</SP> is independently: —H; C1-7alkyl; C3-20heterocycyl; or, C5-20aryl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.Type: ApplicationFiled: December 19, 2002Publication date: October 6, 2005Applicants: VERNALIS (CAMBRIDGE) LIMITED, CANCER RESEARCH TECHNOLOGY LTD., THE INSTITUE OF CANCER RESEARCHInventors: Martin Drysdale, Brian Dymock, Xavier Barril-Alonso, Paul Workman, Laurence Pearl, Chrisostomos Prodromou, Edward Macdonald